Recent Updates
Recently added Catalysts
NRIX Neutral Sentiment

The Evolving Chemical Space of Bi-functional Degraders Targeting the CNS

Key Takeaway: Nurix is focused on translating scientific insights into innovative therapies, particularly in the areas of cancer and autoimmune diseases. The company is advancing its multi-modal portfolio, which includes both wholly owned and partnered assets. They also provide resources related to protein degradation.
Price reaction · baseline $22.335 (2024-10-01T15:03:00.000Z) · hit during market hours · 1 other NRIX headline(s) in the window, move may be shared
day 0 close · peak
-1.1%

Market Sentiment Analysis

POSITIVE FACTORS

  • Focus on novel scientific insights
  • Advancing a multi-modal portfolio
  • Dedicated to breakthrough therapies

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+85%
120-day peak, hindsight
Typical move
4.4%
average across 9 past catalysts
Cash runway
~14 mo
Low dilution risk
Lead asset
NX-5948
Phase 3 · B-cell Lymphoma

Full Press Release Details

RESOURCE LIBRARY
RESOURCE LIBRARY
At Nurix, we are dedicated to translating novel scientific insights into breakthrough therapies, advancing our multi-modal portfolio of wholly owned and partnered assets to outmatch cancer and autoimmune disease. Access our protein degradation resources below.
Filter by

Frequently Asked Questions

What is Nurix focused on?

Nurix is dedicated to translating scientific insights into breakthrough therapies.

What types of diseases does Nurix target?

Nurix targets cancer and autoimmune diseases with its therapies.

What resources does Nurix provide?

Nurix offers resources related to protein degradation.

Last updated: Oct 1, 2024